땅콩 알레르기 치료제 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Peanut Allergy Therapeutic Market

The future of the global peanut allergy therapeutic market looks promising with opportunities in the hospital pharmacy and retail pharmacy markets. The global peanut allergy therapeutic market is expected to reach an estimated $30.7 billion by 2035 from $2.4 billion in 2027 with a CAGR of 37.4% from 2027 to 2035. The major drivers for this market are the increasing prevalence of peanut allergies, the rising demand for effective allergy treatments, and the growing awareness of peanut allergy risks.

• Lucintel forecasts that, within the type category, oral immunotherapy is expected to witness the highest growth over the forecast period due to increasing numbers of clinical teams offering oral immunotherapy.
• Within the distribution channel category, hospital pharmacy is expected to witness higher growth over the forecast period due to increasing prescription volumes from hospital pharmacies.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increasing incidence of peanut allergies, in particular, and other pediatric allergies.

Emerging Trends in Peanut Allergy Therapeutic Market

Between 2025 and 2027 we expect the peanut allergy market to shift from emergency treatments to more ongoing and sustainable treatments. As of now, Palforzia is the only oral peanut allergy treatment available. Other treatments are quickly becoming available. Along with Palforzia, the recent approval of omalizumab to treat food allergies will also shift the market. Lucintel expects how quickly the market shifts will depend on the supplies of allergists, and how strictly payers control reimbursement.

• Ongoing Treatment: As of this year, the only Peanut Allergy treatments available in the U.S. are Palforzia and Omalizumab. The recent approval of Omalizumab means that Peanut Allergy treatments will shift from emergency epinephrine to more long-term treatments.
• Treatments for Food Allergies: DuoBiotic, an anti-IgE treatment for Peanut Allergy, expects to gain approval in 2024, which will further shift the Peanut Allergy treatment market.
• Shifting Norms: Palforzia is approved to be administered to children as young as 1. Early treatment may lower the risk of accidental exposure to peanuts, making a longer treatment window necessary.
• Real World Evidence: There is increasing demand for information on emergency department visits, quality of life, discontinuation, and the household-level impact of allergy symptoms and borers beyond challenge-dose thresholds. During 2025-2027, ongoing post-market studies and registries is expected to inform formulary and reimbursement decisions.
• Delivery Innovation: The continued research has covered other routes of administration including sublingual and epicutaneous. Ease and safety of administration should expand use of these products beyond allergy clinics. Long term compliance, impact on quality of life, and burden on caregivers should impact the market share.

Safety and affordability will play a major role in market dominance. Although currently biologics will not be first-line therapy, they could play a major role in off-label use. Continued education on safety and efficacy will improve market acceptance, especially in pediatric populations. Long term adherence will impact quality of life and reduce the economic burden of the illness.

Recent Developments in the Peanut Allergy Therapeutic Market

The market for peanut allergy therapeutics is anticipated to flourish during the forecast period, with various technologies, including vaccine and biologics-based prevention and Oral Immunotherapy (OIT), creating market excitement. From a business perspective, Lucintel believes that positive momentum will be attributed to a variety of factors, including safer alternatives for children, increased pediatric access, and more effective risk-management strategies, among others.

• Easier Administration of Epinephrine: The FDA's approval of ARS Pharmaceuticals' neffy in August 2024 accelerated the adoption of the nasal-spray-based epinephrine auto-injector. Compared to traditional epinephrine auto-injectors, neffy significantly alleviates the burden associated with the administration of epinephrine in the school and community settings, and facilitates caregiver preparedness. Given the ease of administration of neffy, and other peanut allergy therapies expected to be introduced in the foreseeable future, we believe that caregiver preparedness and awareness will increase.
• OIT's Commercial Success: The success of Palforzia, the only FDA-approved OIT for peanut allergy, will be determined by several factors, including the availability of a sufficient number of trained and qualified clinicians to administer and oversee the treatment. Dependence on specialized allergy centres for the management of OIT will likely influence the competitive dynamics in the marketplace.
• Biologic Prevention Adoption: Xolair received FDA approval in February 2024 for the prevention of allergic reactions to accidental food exposure in individuals 1 year and older. By 2025, pharmaceutical companies began developing biologic therapies for patients who are unsuitable candidates for oral food allergy therapy. Compared to other allergen therapies, biologics have the potential to block multiple allergens and facilitate the shift in allergy therapy to be prolonged and repetitive.
• Epicutaneous Technology: In 2025, DBV Technologies Ltd. advanced the U.S. Food and Drug Administration (FDA) regulatory process for the Viaskin Peanut allergy product. The company conducted its product development for the 250-microgram dose of peanut protein. Viaskin Peanut is intended to treat peanut allergy in children and adolescents who are unable to tolerate introduction of peanut protein in their diet. If approved, Viaskin Peanut would offer children and adolescents a less invasive alternative to other allergen immunotherapies.
• Integrated Diagnostics and Therapy: In 2025, several allergy product companies integrated component-resolved diagnosis and therapy for allergy to peanut by offering the biologic omalizumab (Xolair) to patients. Companies expect that integration of diagnosis and therapy would help reduce unnecessary referrals and assist with third-party payor medical and pharmaceutical coverage decisions. It is expected that component-resolved testing would improve the transition of patients from diagnostic testing to ongoing therapy.

Oral immunotherapy will still be an area of focus in allergy therapy; however, its limitations will be addressed by other allergy therapies. Repetitive and prolonged therapies will be the focus of the allergy therapy industry. Until the completion of clinical trials, reassure the safety of allergy biologics, and address the capacity of allergy specialists, there will be little large-scale commercial allocation of allergy therapy products.

Strategic Growth Opportunities in the Peanut Allergy Therapeutic Market

The market is moving away from peanut allergy management through avoidance. The focus is now on developing therapies to modify peanut allergies. Regulatory agencies and payer organizations, as well as families, are interested in peanut allergy management solutions that provide long-lasting protection. In the 2024-2026 time frame, various market developments are expected from wider commercial opportunities due to the increased use of oral immunotherapy and the introduction of related biopharmaceuticals and diagnostic products.

• Personalized Diagnostic Pathways: There will be increased use of component-resolved testing to help direct peanut allergy management to those in which it is most needed. There will also be increased use of other diagnostic tests to aid in the management of peanut allergies. In January 2025, a large (over 1,000 subjects) diagnostic test study was initiated in Europe.
• Biologic Combination Therapy: The use of a peanut allergy biopharmaceutical, in combination with a biologic, may allow for improved management of peanut allergies. Improved means and methods to reduce peanut allergy will allow for chargeability of these services.
• Risk Treatments for Adults and Teens: The U.S. National Allergy Strategy database shows 2500 adults (February 2025) seeking specialist allergy care for peanut allergy. Employees and their insurers will likely fund allergy care to allow peanut exposure at work and during social and work-related activities.
• Home-based Adherence Solutions: Telehealth and digital solutions will facilitate at-home supervised dosing for Oral Immunotherapy. As of April 2025, a telehealth pilot study to test home-based Oral Immunotherapy for peanut allergy, lasted one year and enrolled 420 participants.
• New Market Development: In May 2025, 800,000 Australians were reported to have food allergies. A similar trend is expected for other developed markets. Initially, Peanut Allergy treatments will find market acceptance in developed countries.

Peanut allergy treatments are expected to increase access to allergy treatments in developed markets. Localized services and solutions will facilitate access in developed markets. Market acceptance for Peanut Allergy treatments will not be influenced by clinical data alone. Payer and provider acceptance will influence market positioning.

Peanut Allergy Therapeutic Market Drivers and Challenges

Peanut Allergy Therapeutics Market is advancing due to rise in the number of diagnoses, the advent of peanut oral immunotherapy, and regulatory and investment-related developments in the allergy industry. Although peanut allergy products are well-positioned to satisfy the increasing demand, numerous barriers have impeded their broad adoption, including high costs, risks associated with the use of unlicensed products, and insufficient insurance reimbursement. Lucintel views the aforementioned barriers will be addressed by product innovation and enhancement of customer service.

The factors responsible for driving this market include:

• Rising Prevalence of Peanut Allergy: The increasing awareness about peanut allergy has been encouraging families to seek preventive treatments. There are evidences that between 2023 and 2025, number of children and families suffering from food allergy and anaphylaxis has increased. In addition, presence of peanut residues and cross contact in the school and community settings have created a safety concern for children with food allergies.
• Immunotherapy Innovation: The use of innovation in immunotherapy has allowed for alternatives to complete avoidance, including the development of various oral and epicutaneous therapies. The clinical development of adolescent and pediatric populations for several peanut allergy immunotherapies is ongoing and is expected to continue in the upcoming years. Improvements in immunotherapy may allow for better trade-offs between dosing convenience, risk, and acceptance by health care professionals and may allow for broader use of peanut allergy treatment.
• Biologic Therapy Expansion: The use of biologic therapies has permitted greater means to modify the allergic response. Omalizumab is currently the only biologic therapy to have been approved to treat peanut allergy and other IgE-mediated allergies in individuals 1 year of age and older. As the use of combination therapies and more favorable immunotherapies become a reality, the biologic therapies may allow for greater means to modify the allergic response.
• Regulatory Changes: Regulatory changes have allowed for more meaningful allergy-related product innovations. Improvements in assessment of risk have allowed for greater consideration of unmet needs, especially in the pediatric population. In 2025, regulatory changes permitted further safety assessments of peanut allergy therapies. It is expected that in the following years greater transparency in assessment of risk will allow for further advancements in the field.
• Therapeutic Product Development: Therapeutic developers target a variety of patient characteristics when developing their products. These include factors related to age, severity of allergy, the patient's level of tolerance to the dose, and patients' lifestyles. It is anticipated that, by 2025, the field of allergy research will focus on shorter and simpler procedures, customized by age. During the next 3-5 years, we may expect personalized allergy products and services for people of all ages.

The challenges facing this market include:

• Safety and Adverse Reactions: There are numerous potential adverse reactions to desensitization therapies. For the peanut allergy market, these therapies are intended to help patients tolerate accidental exposures to peanut proteins, but may, in fact, lead to anaphylaxis. Due to the risks associated with these therapies, federal regulation in 2025 is anticipated to require strict supervision during the initial and continuing phases of treatment.
• High Costs: Therapies to treat peanut allergies are expensive, largely due to the costs of specialist supervision and close monitoring. In addition, there are costs associated with emergency medications and other therapies. Restrictive budgeting and prior authorization policies may further limit access to treatments during the next 3-5 years.
• Limited Allergist Infrastructure: There are numerous factors that contribute to the efficient management of allergic conditions, including adequate numbers of trained medical personnel (i.e. allergists and nurses), equipment and facilities for diagnosing and treating allergic conditions, and follow-up services. In 2025, many countries reported that allergic conditions were managed inadequately because of an uneven regional distribution of allergy specialists and long waiting times. It is expected that, during the next 3 to 5 years, lack of suitable infrastructure would mean that some people would be diagnosed too late or not diagnosed at all and that equity gaps would widen because of a lack of timely access to services and geographic constraints. The situation could improve with telehealth, primary care services, and specialized clinics.

There are many opportunities in the peanut allergy management market with improvements in the biomedical and regulatory environments. While these advances may alter the market negatively (due to costs, risks and/or lack of appropriate services), there are many opportunities to manage peanut allergy. Safety concerns, costs, reimbursement, and the lack of adequate infrastructure would affect market penetration. Most likely, there would be positive, albeit restricted, growth in the market, with the main concerns being the practicality and equity of services offered.

List of Peanut Allergy Therapeutic Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies peanut allergy therapeutic market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peanut allergy therapeutic market companies profiled in this report include-

• Viatris
• Bayer
• UCB Pharma
• J & J
• Perrigo
• GSK
• Kaleo
• Amneal Pharma
• ALK Abello
• Aimmune Therapeutics

Peanut Allergy Therapeutic Market by Segment

The study includes a forecast for the global peanut allergy therapeutic market by type, distribution channel, and region.

Peanut Allergy Therapeutic Market by Type [Value ($B) from 2019 to 2035]:

• Epinephrine Injection
• Antihistamines
• Oral Immunotherapy
• Others

Peanut Allergy Therapeutic Market by Distribution Channel [Value ($B) from 2019 to 2035]:

• Hospital Pharmacy
• Retail Pharmacy
• Others

Peanut Allergy Therapeutic Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Peanut Allergy Therapeutic Market

The peanut allergy market is moving away from avoidance and towards regulated immunotherapy and emergency treatment. The focus of market players is on the development of drugs and delivery systems to treat and prevent peanut allergies in children. Widening access to emergency treatment is expected to gain momentum in the next few years. According to a recent report by Lucintel, the commercial availability of such products is limited due to the slow pace of the regulatory process and the availability of adequate manufacturing capacity.

• United States: The first and only peanut allergy immunotherapy drug, Palforzia, was approved by the FDA in 2020. ARS Pharmaceuticals' neffy, a nondrug alternative form of epinephrine for the treatment of allergic reactions that was approved by the FDA in 2024, is also anticipated to be commercially available from 2025. DBV Technologies is also planning to commercialize its peanut allergy immunotherapy product, Viaskin Peanut, which is pending FDA approval.
• China: The Chinese Food and Drug Administration (CFDA) is also accepting clinical data for peanut allergy immunotherapy drugs. The combination of on-going research at hospitals and the publication of clinical protocols, is likely to facilitate the development of standardized methods to manage peanut allergy in children.
• Germany: The German Society for Allergology and Clinical Immunology endorsed in January 2025, the guidance of health professionals in the management of oral immunotherapy (OIT) for children in selected cases. European clinical practices for Palforzia consist of 12 levels of dose build-up and maintenance. Furthermore, 2025 data demonstrated progress towards the establishment of specialized allergy teams and further facilitated the standardization of OIT across Europe.
• India: Indian allergists pursued oral immunotherapy mainly in the setting of tertiary care. Pharmaceutical companies focused on reliable allergen extracts and ease of access to epinephrine. In 2025, the Central Drugs Standard Control Organization, the regulatory body for drugs in India, mandated a case by case review of applications for marketing authorization of allergen and biologic drugs. This, in the long run, may promote the local production and commercialization of biologics and allergen drugs in India.
• Japan: The use of oral immunotherapy for peanut allergy was limited to few specialized centers in Japan in 2025. Japanese Allergy Clinical Practice Guidelines in 2025 recommended that maintenance dose for peanut allergy should be less than 5 g. These guidelines may positively influence the peanut allergies desensitization service throughout Japan.

Features of the Global Peanut Allergy Therapeutic Market

• Market Size Estimates: peanut allergy therapeutic market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: peanut allergy therapeutic market size by type, distribution channel, and region in terms of value ($B).
• Regional Analysis: peanut allergy therapeutic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, and regions for the peanut allergy therapeutic market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peanut allergy therapeutic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the peanut allergy therapeutic market by type (epinephrine injection, antihistamines, oral immunotherapy, and others), distribution channel (hospital pharmacy, retail pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Peanut Allergy Therapeutic Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Epinephrine Injection : Trends and Forecast 2019 to 2035
• 4.4 Antihistamines : Trends and Forecast 2019 to 2035
• 4.5 Oral Immunotherapy : Trends and Forecast 2019 to 2035
• 4.6 Others : Trends and Forecast 2019 to 2035

5. Global Peanut Allergy Therapeutic Market by Distribution Channel

• 5.1 Overview
• 5.2 Attractiveness Analysis by Distribution Channel
• 5.3 Hospital Pharmacy : Trends and Forecast 2019 to 2035
• 5.4 Retail Pharmacy : Trends and Forecast 2019 to 2035
• 5.5 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Peanut Allergy Therapeutic Market by Region

7. North American Peanut Allergy Therapeutic Market

• 7.1 Overview
• 7.2 North American Peanut Allergy Therapeutic Market by Type
• 7.3 North American Peanut Allergy Therapeutic Market by Distribution Channel
• 7.4 The United States Peanut Allergy Therapeutic Market
• 7.5 Canadian Peanut Allergy Therapeutic Market
• 7.6 Mexican Peanut Allergy Therapeutic Market

8. European Peanut Allergy Therapeutic Market

• 8.1 Overview
• 8.2 European Peanut Allergy Therapeutic Market by Type
• 8.3 European Peanut Allergy Therapeutic Market by Distribution Channel
• 8.4 German Peanut Allergy Therapeutic Market
• 8.5 French Peanut Allergy Therapeutic Market
• 8.6 Italian Peanut Allergy Therapeutic Market
• 8.7 Spanish Peanut Allergy Therapeutic Market
• 8.8 The United Kingdom Peanut Allergy Therapeutic Market

9. APAC Peanut Allergy Therapeutic Market

• 9.1 Overview
• 9.2 APAC Peanut Allergy Therapeutic Market by Type
• 9.3 APAC Peanut Allergy Therapeutic Market by Distribution Channel
• 9.4 Chinese Peanut Allergy Therapeutic Market
• 9.5 Indian Peanut Allergy Therapeutic Market
• 9.6 Japanese Peanut Allergy Therapeutic Market
• 9.7 South Korean Peanut Allergy Therapeutic Market
• 9.8 Indonesian Peanut Allergy Therapeutic Market

10. ROW Peanut Allergy Therapeutic Market

• 10.1 Overview
• 10.2 ROW Peanut Allergy Therapeutic Market by Type
• 10.3 ROW Peanut Allergy Therapeutic Market by Distribution Channel
• 10.4 Middle Eastern Peanut Allergy Therapeutic Market
• 10.5 South American Peanut Allergy Therapeutic Market
• 10.6 African Peanut Allergy Therapeutic Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Distribution Channel
• 12.3 Emerging Trends in the Global Peanut Allergy Therapeutic Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Viatris
  • Company Overview
  • Peanut Allergy Therapeutic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Bayer
  • Company Overview
  • Peanut Allergy Therapeutic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 UCB Pharma
  • Company Overview
  • Peanut Allergy Therapeutic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 J & J
  • Company Overview
  • Peanut Allergy Therapeutic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Perrigo
  • Company Overview
  • Peanut Allergy Therapeutic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 GSK
  • Company Overview
  • Peanut Allergy Therapeutic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Kaleo
  • Company Overview
  • Peanut Allergy Therapeutic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Amneal Pharma
  • Company Overview
  • Peanut Allergy Therapeutic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 ALK Abello
  • Company Overview
  • Peanut Allergy Therapeutic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Aimmune Therapeutics
  • Company Overview
  • Peanut Allergy Therapeutic Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us